Presentations
Snelder N., Ploeger B., Danhof M., Stanski D., Rigel D., Webb R., Feldman D. and Luttringer O., Drug effects on the Cardiovascular system – development of a mechanism-based pharmacodynamic model to improve translational drug research. Noordwijkerhout.(2010)
Jongh J.d. and Ploeger B., A population PD model for effects of the cytostatic drugs Irinotecan and Temozolomide on Rh18 rabdomyosarcoma xenografts in mice. Noordwijkerhout.(2010).
Stringer F., Jongh J.d, Ploeger B., Scott G., Urquart R. and Danhof M., Clinical impact of genetic polymorphisms observed in the pharmacokinetics of the novel PPAR agonist, Sipoglitazar. Noordwijkerhout.(2010)
Press R.R., Rossum H.H. v., Ploeger B.A., Hartigh J.d., Pelt J.v., Guchelaar H.J., Fijter J.W.d. and Danhof M., Is Calcineurin activity useful as a biomarker to optimize cyclosporine a therapy in renal transplant recipients? PAGE.(2009).[Link to publication]
Snelder N., Diack C., Benson N., Ploeger B.and Graaf P.v.d., Towards the implementation of the Markov property into a continuous-time transition state model in NONMEM. PAGE.(2009). [Link to publication]
Liefaard L., Huntjens D., Vermeulen A. and Drenth H., Modelling non-linear dose-dependent absorption profiles after oral prolonged release formulations. PAGE.(2009).[Link to publication]
Snelder N., Steeg T.v., Ploeger B., Atkins N. and Graaf P.v.d., Safety pharmacology screening using a standardized population pharmacokineticpharmacodynamic modelling approach. PAGE.(2009). [Link to publication]
Stringer F., Ploeger B., Jongh J.d., Scott G., Urquart R., Karim A. and Danhof M., Genotyped versus phenotyped dosing to account for UGT polymorphism of the novel PPAR agonist sipoglitazar PAGE.(2009). [Link to publication]
Stringer F., Ploeger B., Scott G., Kawamura M. and Kupfer S., Pharmacokinetic and pharmacodynamic modeling of the novel oral direct factor Xa inhibitor TAK-442. ASCPT (2009).
Smeets J., Ploeger B., Strougo A., Liefaard L. and Kerbusch T., A Mechanism-based Pharmacokinetic Model Describing the Interaction Between Sugammadex and Rocuronium in Patients with Normal and Impaired Renal Function. PAGE.(2008). [Link to publication]